IP Library Granted Patent US 9,486,452
Granted Patent B2
US 9,486,452 · App. 14/209,937 · Granted Nov 8, 2016

Product and method for treating diarrhea

Inventor: Reed B Hogan, II (Jackson, MS)
Assignee: MAREGADE RX, LLC
A61K31/495A61K31/341A61K31/426
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,486,452
App. No.
14/209,937
Granted
Nov 8, 2016
Kind
B2
Abstract

A method of treating diarrhea in a patient includes administering an H1 receptor antagonist and an H2 receptor antagonist to the patient.

Claims (22)

1. A method of treating diarrhea in a patient, comprising administering an H1 receptor antagonist and an H2 receptor antagonist to the patient, wherein the patient does not have mastocytic enterocolitis, and the patient has chemotherapy induced diarrhea.

2. The method of claim 1 , wherein the H1 receptor antagonist comprises a second-generation H1 receptor antagonist.

3. The method of claim 1 , wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof.

4. The method of claim 1 , wherein the H2 receptor antagonist comprises famotidine, ranitidine, or mixtures thereof.

5. The method of claim 1 , wherein the H1 receptor antagonist and the H2 receptor antagonist are administered simultaneously.

6. The method of claim 1 , wherein the H1 receptor antagonist and the H2 receptor antagonist are administered once per day for at least 2 days.

7. The method of claim 1 , wherein the H1 receptor antagonist and the H2 receptor antagonist are administered once per day for at least 7 days.

8. The method of claim 1 , wherein the patient has chronic diarrhea.

9. The method of claim 1 , wherein the patient has acute diarrhea.

10. A method of treating diarrhea in a patient, comprising administering an H1 receptor antagonist and an H2 receptor antagonist to the patient, wherein the H1 receptor antagonist comprises cetirizine and the H2 receptor antagonist comprises famotidine, and the patient has chemotherapy induced diarrhea,

wherein the H1 receptor antagonist and the H2 receptor antagonist are administered simultaneously.

11. The method of claim 10 , wherein the H1 receptor antagonist and the H2 receptor antagonist are administered once per day for at least 2 days.

12. The method of claim 10 , wherein the H1 receptor antagonist and the H2 receptor antagonist are administered once per day for at least 7 days.

13. The method of claim 10 , wherein the patient has chronic diarrhea.

14. The method of claim 10 , wherein the patient has acute diarrhea.

15. The method of claim 10 , wherein cetirizine is administered in an amount of 5 to 20 mg.

16. The method of claim 10 , wherein the famotidine is administered in an amount of 10 to 40 mg.

17. The method of claim 10 , wherein the famotidine and the cetirizine are administered together as a unit dosage form.

18. The method of claim 1 , wherein the H1 receptor antagonist and the H2 receptor antagonist are administered together as a unit dosage form.

19. The method of claim 17 , wherein the patient has chronic diarrhea.

20. The method of claim 1 , wherein the H1 receptor antagonist comprises cetirizine, and the cetirizine is administered in an amount of 5 to 20 mg.

21. The method of claim 1 , wherein the H2 receptor antagonist comprises famotidine, and the famotidine is administered in an amount of 10 to 40 mg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2014
From: HOGAN II, REED B.
To: MAREGADE RX, LLC
Reel/Frame 032434/0454 →
Continuity (2)
Provisional Application 61782608 · Mar 14, 2013
Related Publication 20140275116A1 · Sep 18, 2014